WO2004019946A1 - 細胞内ナトリウムイオン過蓄積抑制薬 - Google Patents
細胞内ナトリウムイオン過蓄積抑制薬 Download PDFInfo
- Publication number
- WO2004019946A1 WO2004019946A1 PCT/JP2003/011010 JP0311010W WO2004019946A1 WO 2004019946 A1 WO2004019946 A1 WO 2004019946A1 JP 0311010 W JP0311010 W JP 0311010W WO 2004019946 A1 WO2004019946 A1 WO 2004019946A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- acid
- sodium ion
- agent
- intracellular sodium
- Prior art date
Links
- 229910001415 sodium ion Inorganic materials 0.000 title claims abstract description 42
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 title claims abstract description 40
- 239000003112 inhibitor Substances 0.000 title claims abstract description 22
- 238000009825 accumulation Methods 0.000 title claims abstract description 18
- 239000004480 active ingredient Substances 0.000 claims abstract description 21
- 150000003839 salts Chemical class 0.000 claims abstract description 20
- 208000019622 heart disease Diseases 0.000 claims abstract description 10
- ZMCHBSMFKQYNKA-UHFFFAOYSA-N 2-aminobenzenesulfonic acid Chemical class NC1=CC=CC=C1S(O)(=O)=O ZMCHBSMFKQYNKA-UHFFFAOYSA-N 0.000 claims abstract description 8
- 230000003449 preventive effect Effects 0.000 claims abstract description 4
- 238000001356 surgical procedure Methods 0.000 claims abstract 2
- 230000003834 intracellular effect Effects 0.000 claims description 54
- 239000003795 chemical substances by application Substances 0.000 claims description 29
- 150000001875 compounds Chemical class 0.000 claims description 29
- 239000002253 acid Substances 0.000 claims description 22
- -1 1-piperazinyl Chemical group 0.000 claims description 18
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 18
- 238000007675 cardiac surgery Methods 0.000 claims description 17
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 claims description 16
- 229940092714 benzenesulfonic acid Drugs 0.000 claims description 16
- 125000000217 alkyl group Chemical group 0.000 claims description 15
- 206010019280 Heart failures Diseases 0.000 claims description 13
- 125000005843 halogen group Chemical group 0.000 claims description 13
- 230000000069 prophylactic effect Effects 0.000 claims description 13
- 230000001225 therapeutic effect Effects 0.000 claims description 13
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 12
- 239000011734 sodium Substances 0.000 claims description 12
- 229910052708 sodium Inorganic materials 0.000 claims description 12
- 208000028867 ischemia Diseases 0.000 claims description 11
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 11
- 208000031225 myocardial ischemia Diseases 0.000 claims description 11
- 239000012453 solvate Substances 0.000 claims description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims description 9
- 208000020446 Cardiac disease Diseases 0.000 claims description 9
- 229910001424 calcium ion Inorganic materials 0.000 claims description 9
- 201000010099 disease Diseases 0.000 claims description 9
- 206010003119 arrhythmia Diseases 0.000 claims description 8
- 230000006793 arrhythmia Effects 0.000 claims description 8
- 238000006467 substitution reaction Methods 0.000 claims description 8
- 206010020772 Hypertension Diseases 0.000 claims description 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 7
- 230000002265 prevention Effects 0.000 claims description 7
- 125000001424 substituent group Chemical group 0.000 claims description 7
- 229940124597 therapeutic agent Drugs 0.000 claims description 7
- 238000011282 treatment Methods 0.000 claims description 7
- 206010063837 Reperfusion injury Diseases 0.000 claims description 6
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 6
- 206010002383 Angina Pectoris Diseases 0.000 claims description 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 4
- 229910052801 chlorine Inorganic materials 0.000 claims description 4
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 4
- 208000010125 myocardial infarction Diseases 0.000 claims description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 4
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 4
- 125000003277 amino group Chemical group 0.000 claims description 3
- 125000003118 aryl group Chemical group 0.000 claims description 3
- 210000004413 cardiac myocyte Anatomy 0.000 claims description 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 3
- 239000005858 Triflumizole Substances 0.000 claims description 2
- HSMVPDGQOIQYSR-KGENOOAVSA-N triflumizole Chemical compound C1=CN=CN1C(/COCCC)=N/C1=CC=C(Cl)C=C1C(F)(F)F HSMVPDGQOIQYSR-KGENOOAVSA-N 0.000 claims description 2
- 150000004677 hydrates Chemical class 0.000 claims 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims 3
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 2
- 150000004682 monohydrates Chemical class 0.000 claims 2
- RPVXLEZMIXHFPG-UHFFFAOYSA-N 2-piperazin-1-ylbenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1N1CCNCC1 RPVXLEZMIXHFPG-UHFFFAOYSA-N 0.000 claims 1
- 125000002774 3,4-dimethoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C(OC([H])([H])[H])=C1OC([H])([H])[H])C([H])([H])* 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- 239000002904 solvent Substances 0.000 abstract description 2
- 235000002639 sodium chloride Nutrition 0.000 description 21
- 230000010410 reperfusion Effects 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000011084 recovery Methods 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 230000008602 contraction Effects 0.000 description 4
- 230000002861 ventricular Effects 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 208000031229 Cardiomyopathies Diseases 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 230000000747 cardiac effect Effects 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- MVIOINXPSFUJEN-UHFFFAOYSA-N benzenesulfonic acid;hydrate Chemical compound O.OS(=O)(=O)C1=CC=CC=C1 MVIOINXPSFUJEN-UHFFFAOYSA-N 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000004217 heart function Effects 0.000 description 2
- 125000003707 hexyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000003680 myocardial damage Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical class NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- XHRCFGDFESIFRG-UHFFFAOYSA-N 2-chloro-n-ethyl-n-[(2-methylphenyl)methyl]ethanamine Chemical class ClCCN(CC)CC1=CC=CC=C1C XHRCFGDFESIFRG-UHFFFAOYSA-N 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- ZRQKZWAOIRVBFD-UHFFFAOYSA-N 5-methyl-2-piperazin-1-ylbenzenesulfonic acid;hydrate Chemical compound O.OS(=O)(=O)C1=CC(C)=CC=C1N1CCNCC1 ZRQKZWAOIRVBFD-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- 208000014526 Conduction disease Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- BWLUMTFWVZZZND-UHFFFAOYSA-N Dibenzylamine Chemical class C=1C=CC=CC=1CNCC1=CC=CC=C1 BWLUMTFWVZZZND-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 108010052164 Sodium Channels Proteins 0.000 description 1
- 102000018674 Sodium Channels Human genes 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- VEUACKUBDLVUAC-UHFFFAOYSA-N [Na].[Ca] Chemical group [Na].[Ca] VEUACKUBDLVUAC-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- XSDQTOBWRPYKKA-UHFFFAOYSA-N amiloride Chemical compound NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N XSDQTOBWRPYKKA-UHFFFAOYSA-N 0.000 description 1
- 229960002576 amiloride Drugs 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000008081 blood perfusion Effects 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000001964 calcium overload Effects 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 230000003683 cardiac damage Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000003205 diastolic effect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- WCDWBPCFGJXFJZ-UHFFFAOYSA-N etanidazole Chemical group OCCNC(=O)CN1C=CN=C1[N+]([O-])=O WCDWBPCFGJXFJZ-UHFFFAOYSA-N 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000000745 ion overload Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000028161 membrane depolarization Effects 0.000 description 1
- 230000004065 mitochondrial dysfunction Effects 0.000 description 1
- 210000002464 muscle smooth vascular Anatomy 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000004923 naphthylmethyl group Chemical group C1(=CC=CC2=CC=CC=C12)C* 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000001908 sarcoplasmic reticulum Anatomy 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 125000004205 trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
Definitions
- the present invention relates to an agent for suppressing intracellular sodium ion hyperaccumulation, and an agent for treating and / or preventing a cardiac disorder associated with cardiac surgery.
- intracellular sodium overload intracellular sodium overload
- Intracellular sodium perload subsequently causes intracellular calcium ion over-accumulation (hereinafter sometimes referred to as intracellular calcium overload), mitochondrial dysfunction, cell membrane depolarization, etc.
- Aminobenzenesulfonic acid derivatives having an effective action are known (JP-A-3-7263). These compounds have no i8 receptor stimulant-like action, ⁇ -receptor blocker-like action, or calcium channel antagonist-like action to suppress or reduce cardiomyopathy, cardiac stimulus conduction disorder, etc. However, it is disclosed that it can be a useful prophylactic or therapeutic agent for ischemic heart disease (eg, myocardial infarction, angina pectoris, etc.), heart failure, hypertension, arrhythmia, etc. (Japanese Patent Application Laid-Open No. Hei 3-7263 and Kaihei 4-139127).
- Japanese Patent Application Laid-Open No. Hei 10-298077 discloses that the compound has an effect of remarkably improving cardiac function deterioration under cardiomyopathy conditions, and also has a long-term survival rate in sudden cardiomyopathy. improved, that force s have the effect of prolonging, further, International Patent Publication WO99 / 40919, the compound has calcium I on the uptake-promoting effect in cardiac sarcoplasmic reticulum. the treatment or prevention of diastolic failure It is disclosed that it is useful.
- An object of the present invention is to provide a medicament for suppressing intracellular sodium ion hyperaccumulation, and a therapeutic and / or preventive agent for cardiac disorders associated with cardiac surgery.
- the present inventors have made intensive efforts to achieve the above object, and as a result, have found that a specific aminobenzene sulfonic acid derivative, a salt thereof, or a hydrate or solvate thereof has an inhibitory action on intracellular sodium ion overaccumulation.
- the present invention was found and completed.
- the gist of the present invention is represented by the following general formula (I) ... (I)
- R 2 is a hydrogen atom, —C 6 alkynole, or cyano, nitro, C 6 alkoxy, halogen, C—C 6 alkyl, and amino; 2 or more but it may also have a substituent group C 7 - represents a second Ararukiru group; n represents an integer of 1 to 4)
- the intracellular sodium ion hyperaccumulation inhibitor is an intracellular sodium ion hyperaccumulation inhibitor for treatment and / or prevention of ischemia / reperfusion injury; and ischemia / reperfusion injury It is an inhibitor of the intracellular sodium ion hyperaccumulation, which is an inhibitor of the increase in the sodium content of the cardiac muscle cell induced by the above.
- a disease caused by intracellular sodium ion hyperaccumulation containing the above-mentioned inhibitor of intracellular sodium ion hyperaccumulation as an active ingredient (excluding ischemic heart disease, heart failure, hypertension and arrhythmia)
- An agent for treating and / or preventing a circulatory disease caused by intracellular calcium ion hyperaccumulation following intracellular sodium ion hyperaccumulation excluding ischemic heart disease, heart failure, hypertension and arrhythmia
- the present invention is a therapeutic and / or prophylactic agent for cardiac disorders associated with cardiac surgery, which contains, as an active ingredient, the aminobenzene sulfonic acid derivative represented by the above general formula (I). .
- the present invention provides an agent for suppressing intracellular sodium ion hyperaccumulation, and an agent for treating and / or preventing a cardiac disorder associated with cardiac surgery.
- the compound represented by the above general formula (I) Since it has an effect of suppressing hyperaccumulation, it is effective in treating and / or preventing ischemia / reperfusion injury.
- the compound represented by the above general formula (I) has an inhibitory action on intracellular sodium ion accumulation, diseases caused by intracellular sodium ion accumulation (however, ischemic heart disease, heart failure, hypertension and arrhythmia) Is effective for the treatment and / or prevention of
- intra-cellular sodium ion over-accumulation causes intra-cellular calcium ion over-accumulation
- circulatory diseases caused by intra-cellular calcium ion over-accumulation following intra-cellular sodium ion over-accumulation more specifically, For example, it is also effective in treating and / or preventing ischemic heart disease, heart failure, hypertension, arrhythmia, and the like.
- ischemic heart disease include myocardial infarction and angina.
- Examples of the active ingredient of the drug of the present invention include the amino benzene sulfonic acid derivative represented by the above general formula (I) or a salt thereof, or a hydrate or a solvate thereof.
- the general formula (I) as the ⁇ Norekiru group d-c s as defined in 1 ⁇ , for example, a methyl group, Echiru group, a propyl group, an isopropyl group, butyl group, isobutyl group, sec- butyl group, Examples include a tert-butynole group, a pentyl group, an isopentyl group, a neopentyl group, a tert-pentynole group, a hexyl group, and an isohexyl group.
- Examples of the C 3 -C 7 cycloalkyl group include a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, a cyclohexynole group, a cycloheptyl group, and the like.
- Examples of the C x -C 4 halogenated alkyl group include a trifluoromethylol group, a trifluoroethyl group, a pentafluoroethyl group, and the like.
- Examples of the halogen atom include a fluorine atom, a chlorine atom, and a bromine atom.
- Examples of the aryl group of c 6 to c 12 include a phenyl group and a naphthyl group.
- Preferred examples of 1 ⁇ include a hydrogen atom, an alkyl group of Ci—Cs, an alkyl group of c 5 _c 6, a methyl group of trifluoro, a halogen atom and a phenyl group.
- R is an alkyl group of C i one C 3, carboxymethyl Le group cycloheteroalkyl, triflumizole Ruo Russia methyl group, a chlorine atom, a bromine atom or a phenyl group, Particularly, it is preferably a methyl group or a propyl group.
- the substitution position of 1 ⁇ is preferably at the 5-position.
- Examples of the 1 C 6 alkyl group defined for R 2 include the alkyl groups defined for 1 ⁇ above.
- C The Ararukiru group one C 1 2, if example embodiment, a benzyl group, phenethyl group, etc. naphthylmethyl group.
- the aralkyl group may be a cyano group; a nitro group; Ci-C 6 alkoxy group such as hexoxy group, hexyloxy group, etc .; halogen atom as defined in 1 ⁇ above; one or two selected from the group consisting of alkyl group and amino group as defined above It may have the above substituents.
- R 2 examples include a hydrogen atom, a C—C 3 alkyl group, and a ⁇ ⁇ —C 3 alkyl group.
- a C 7 -C 12 aralkyl group which may have one or more substituents selected from a C 3 alkoxy group and a halogen atom is more preferable.
- R 2 is preferably a hydrogen atom Or a C 7 —C 12 aralkyl group which may be substituted with one or more C—C 3 alkoxy groups, and particularly preferably a hydrogen atom.
- n is preferably 2.
- Preferred specific examples of the present invention include the compounds shown in Tables 1 and 2 below.
- Preferred compounds include the following compounds.
- particularly preferred examples include 5-methinolay 2- (1-1piperazinyl) benzenesulfonic acid and 5-n-propyl-12- (1-1piperazinyl) benzenesnolephonic acid.
- salts of the above compounds include, for example, alkali metal salts such as sodium salt, potassium salt, magnesium salt, calcium salt and aluminum salt or alkaline earth metal salts; lower alkylamines such as ammonium salt and triethylamine salt Hydroxy lower alkylamine salts such as salt, 2-hydroxylethylamine salt, bis- (2-hydroxyletchinole) amine salt, tris (hydroxymethylinole) aminolamine salt, N-methyl-1-D-glucamine salt, etc.
- alkali metal salts such as sodium salt, potassium salt, magnesium salt, calcium salt and aluminum salt or alkaline earth metal salts
- lower alkylamines such as ammonium salt and triethylamine salt Hydroxy lower alkylamine salts such as salt, 2-hydroxylethylamine salt, bis- (2-hydroxyletchinole) amine salt, tris (hydroxymethylinole) aminolamine salt, N-methyl-1-D-glucamine salt, etc.
- Amine salts such as cycloanolequinoleamine salts such as xylamine salts, benzinoleamine salts such as N, N-dipendinoleethylenediamine salts, and dibenzylamine salts; hydrochlorides, hydrobromides, sulfates, and phosphorus Inorganic salts such as acid salts; or organic acid salts such as fumarate, succinate, oxalate and lactate. It is. .
- any hydrate or solvate thereof may be used as an active ingredient of the medicament of the present invention, in addition to a salt or a compound in a free form.
- the solvent capable of forming a solvate of the above compound include methanol, ethanol, isopropyl alcohol, acetone, ethyl acetate, methylene chloride and the like.
- the most preferred active ingredient of the medicament of the present invention is 5-methyl-2- (1-pidazul) benzenesulfonic acid monohydrate.
- the amino benzene sulfonic acid derivative represented by the general formula (I) is a known compound, for example, JP-A-3-7263 and JP-A-9-221479, European Patent Application Publication Nos. 390654 and 779283. And the methods described in US Patent Publication Nos. 5053409 and 5990113, etc. It is a compound that can be obtained from
- the therapeutic and / or prophylactic agent of the present invention is orally or parenterally applied to humans by a conventional method.
- Dosage forms for oral administration include granules, fine granules, powders, tablets, hard capsules, soft capsules, syrups, emulsions, suspensions or liquids, and the like.
- examples of dosage forms for parenteral administration include injections, suppositories, and transdermals.
- the active ingredient of the present invention may be a solid or liquid pharmaceutical carrier or excipient, a stabilizer, a lubricant, a sweetener, a preservative, a suspending agent and the like, which are commonly used in the above-mentioned dosage form.
- the content of the therapeutically or prophylactically active ingredient in the carrier component is preferably in the range of 1% by weight to 90% by weight.
- solid components used include lactose, china clay, sucrose, crystalline cellulose, corn starch, talc, agar, pectin, acacia, stearic acid, magnesium stearate, lecithin, sodium chloride and the like.
- liquid carriers include syrup, glycerin, peanut oil, polyvinylpyrrolidone, olive oil, ethanol, benzyl alcohol, propylene glycol, water and the like.
- the dose of the substance to be used as the active ingredient may be appropriately determined for each active ingredient, taking into account the purpose of treatment or prevention, the type of disease to be treated or prevented, the patient's symptoms, weight, age, sex, etc. Taking the compound represented by the above general formula (I) as a typical example, usually about 0.01 mg to 100 mg per day can be administered orally per adult per day. It is desirable to administer such a dose in one or several divided doses per day.
- MCC-135J 5-methyl-1- (1-pi Radinyl) benzenesulfonic acid monohydrate
- Rat hearts are excised and Krebs Buffer according to the Langendorff method
- Amiloride (a sodium-proton exchange inhibitor) (purchased from Sigma (St. Louis, M USA, USA)) improved the reduction in contractile tension recovery at a high dose, but did not increase the ventricular sodium content. Had no effect.
- Table 3 Effects of CC-135 on ventricular calcium content and contractile tension recovery
- the compound of the present invention is effective in suppressing the increase of sodium ion content in cardiomyocytes induced by blood / reperfusion It was shown.
- an agent for suppressing intracellular sodium ion hyperaccumulation can be provided, and the agent of the present invention can be used for the treatment of disorders caused by ischemia and reperfusion that occur in clinical practice, and for Z or prophylaxis or cardiac surgery. It is effective in treating and / or preventing heart failure.
- hyper-accumulation of intracellular sodium ions causes hyper-accumulation of intracellular calcium ions, which results in circulatory system diseases such as ischemic heart disease, heart failure, hypertension and arrhythmia caused by hyper-accumulation of intracellular calcium ions. It is effective for treatment and prevention or prevention.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/525,980 US20060167013A1 (en) | 2002-08-30 | 2003-08-29 | Inhibitors for excessive accumulation of sodium ion in cells |
JP2004532768A JPWO2004019946A1 (ja) | 2002-08-30 | 2003-08-29 | 細胞内ナトリウムイオン過蓄積抑制薬 |
AU2003261815A AU2003261815A1 (en) | 2002-08-30 | 2003-08-29 | Inhibitors for excessive accumulation of sodium ion in cells |
US11/984,414 US20080114000A1 (en) | 2002-08-30 | 2007-11-16 | Suppressor of excess accumulation of intracellular sodium ions |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002-255746 | 2002-08-30 | ||
JP2002255746 | 2002-08-30 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/984,414 Continuation US20080114000A1 (en) | 2002-08-30 | 2007-11-16 | Suppressor of excess accumulation of intracellular sodium ions |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004019946A1 true WO2004019946A1 (ja) | 2004-03-11 |
Family
ID=31972913
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2003/011010 WO2004019946A1 (ja) | 2002-08-30 | 2003-08-29 | 細胞内ナトリウムイオン過蓄積抑制薬 |
Country Status (4)
Country | Link |
---|---|
US (2) | US20060167013A1 (ja) |
JP (1) | JPWO2004019946A1 (ja) |
AU (1) | AU2003261815A1 (ja) |
WO (1) | WO2004019946A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPWO2004022545A1 (ja) * | 2002-09-06 | 2005-12-22 | 三菱ウェルファーマ株式会社 | 移植臓器保護剤 |
WO2008032814A1 (fr) * | 2006-09-14 | 2008-03-20 | Mitsubishi Tanabe Pharma Corporation | Agent pharmaceutique contenant de l'aspirine |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0390654A1 (en) * | 1989-03-27 | 1990-10-03 | Mitsubishi Chemical Corporation | Aminobenzenesulfonic acid derivative |
JPH04139127A (ja) * | 1990-09-27 | 1992-05-13 | Mitsubishi Kasei Corp | 心疾患を予防または治療する薬剤 |
EP0779283A1 (en) * | 1995-12-15 | 1997-06-18 | Mitsubishi Chemical Corporation | Monohydrates of aminobenzenesulfonic acid derivatives and method for preparation thereof |
EP1062948A1 (en) * | 1998-02-12 | 2000-12-27 | Mitsubishi Chemical Corporation | Remedies for cardiac dilastolic disorders |
WO2002072097A1 (fr) * | 2001-03-13 | 2002-09-19 | Mitsubishi Pharma Corporation | Remedes et/ou medicaments preventifs pour des cardiopathies ischemiques diabetiques |
WO2003009897A1 (en) * | 2001-07-25 | 2003-02-06 | Mitsubishi Pharma Corporation | Medicament inhibiting sodium/calcium exchange system |
WO2003011296A1 (en) * | 2001-07-30 | 2003-02-13 | Mitsubishi Pharma Corporation | Pharmaceutical preparations containing aminobenzene- sulfonic acid derivatives as the active ingredient |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5053409A (en) * | 1989-03-27 | 1991-10-01 | Mitsubishi Kasei Corporation | Aminobenzenesulfonic acid derivatives |
US20030148968A1 (en) * | 1995-02-28 | 2003-08-07 | Hammond H. Kirk | Techniques and compositions for treating cardiovascular disease by in vivo gene delivery |
JP3215338B2 (ja) * | 1995-12-15 | 2001-10-02 | 三菱化学株式会社 | アミノベンゼンスルホン酸誘導体一水和物及びその製造方法 |
JPH10298077A (ja) * | 1997-04-24 | 1998-11-10 | Mitsubishi Chem Corp | 心筋症の治療、予防剤 |
-
2003
- 2003-08-29 WO PCT/JP2003/011010 patent/WO2004019946A1/ja active Application Filing
- 2003-08-29 JP JP2004532768A patent/JPWO2004019946A1/ja active Pending
- 2003-08-29 US US10/525,980 patent/US20060167013A1/en not_active Abandoned
- 2003-08-29 AU AU2003261815A patent/AU2003261815A1/en not_active Abandoned
-
2007
- 2007-11-16 US US11/984,414 patent/US20080114000A1/en not_active Abandoned
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0390654A1 (en) * | 1989-03-27 | 1990-10-03 | Mitsubishi Chemical Corporation | Aminobenzenesulfonic acid derivative |
JPH04139127A (ja) * | 1990-09-27 | 1992-05-13 | Mitsubishi Kasei Corp | 心疾患を予防または治療する薬剤 |
EP0779283A1 (en) * | 1995-12-15 | 1997-06-18 | Mitsubishi Chemical Corporation | Monohydrates of aminobenzenesulfonic acid derivatives and method for preparation thereof |
EP1062948A1 (en) * | 1998-02-12 | 2000-12-27 | Mitsubishi Chemical Corporation | Remedies for cardiac dilastolic disorders |
WO2002072097A1 (fr) * | 2001-03-13 | 2002-09-19 | Mitsubishi Pharma Corporation | Remedes et/ou medicaments preventifs pour des cardiopathies ischemiques diabetiques |
WO2003009897A1 (en) * | 2001-07-25 | 2003-02-06 | Mitsubishi Pharma Corporation | Medicament inhibiting sodium/calcium exchange system |
WO2003011296A1 (en) * | 2001-07-30 | 2003-02-13 | Mitsubishi Pharma Corporation | Pharmaceutical preparations containing aminobenzene- sulfonic acid derivatives as the active ingredient |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPWO2004022545A1 (ja) * | 2002-09-06 | 2005-12-22 | 三菱ウェルファーマ株式会社 | 移植臓器保護剤 |
WO2008032814A1 (fr) * | 2006-09-14 | 2008-03-20 | Mitsubishi Tanabe Pharma Corporation | Agent pharmaceutique contenant de l'aspirine |
Also Published As
Publication number | Publication date |
---|---|
US20080114000A1 (en) | 2008-05-15 |
JPWO2004019946A1 (ja) | 2005-12-15 |
US20060167013A1 (en) | 2006-07-27 |
AU2003261815A1 (en) | 2004-03-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1773341A1 (en) | Piperazine derivatives for the treatment of female sexual disorders | |
JP5643213B2 (ja) | 肥大性心筋症治療用のホスホジエステラーゼタイプIII(PDEIII)インヒビターまたはCa2+感作剤 | |
JP4246997B2 (ja) | 糖尿病由来虚血性心疾患の治療及び/または予防剤 | |
WO2004019946A1 (ja) | 細胞内ナトリウムイオン過蓄積抑制薬 | |
US7772258B2 (en) | Agent for treatment of allergic eye disease | |
KR20060125862A (ko) | 심방 수축력의 선택적 증가 및 심부전증 치료를 위한Kv1.5-차단제 | |
US10849902B2 (en) | Medicament for treating heart failure | |
JP2004538292A (ja) | ナトリウム・カルシウム交換系を阻害する医薬 | |
EP0744950A1 (en) | Agent for prophylaxis and treatment of thromboxane a 2?-mediated diseases | |
WO2001045739A1 (fr) | Remedes et/ou medicaments preventifs pour troubles du systeme nerveux | |
WO2004022545A1 (ja) | 移植臓器保護剤 | |
KR100219972B1 (ko) | 빈혈과 관련된 조직 손상 감소 방법 | |
WO2008032814A1 (fr) | Agent pharmaceutique contenant de l'aspirine | |
JPWO2005084668A1 (ja) | 虚血性循環器疾患の予防及び/又は治療のための薬剤 | |
JP4713859B2 (ja) | ミトコンドリア脳筋症の治療及び/又は予防剤 | |
JP2006096664A (ja) | 肝繊維化抑制剤 | |
WO2003080583A1 (fr) | Medicament pour prevenir et/ou traiter une cardiomyopathie | |
US20190282558A1 (en) | Methods of Treating Zika Virus Infection | |
JPS6132287B2 (ja) | ||
JP2003267871A (ja) | 放射線障害予防剤 | |
WO2018016611A1 (ja) | 緑内障治療薬 | |
JP2004137253A (ja) | 心筋炎の予防及び/又は治療のための医薬 | |
JP2006298786A (ja) | 2−メチル−1,3,4−チアジアゾール−5−チオール生成抑制剤 | |
WO2002072099A1 (fr) | Agent therapeutique et / ou prophylactique pour la cardiopathie ischemique diabetique | |
JP2004115511A (ja) | ピラゾロン誘導体を有効成分とするナトリウム・カルシウム交換系阻害剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004532768 Country of ref document: JP |
|
ENP | Entry into the national phase |
Ref document number: 2006167013 Country of ref document: US Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10525980 Country of ref document: US |
|
122 | Ep: pct application non-entry in european phase | ||
WWP | Wipo information: published in national office |
Ref document number: 10525980 Country of ref document: US |